POSTERIOR SUB-TENON'S Avastin

Phase 4WithdrawnNCT00567372

Asociación para Evitar la Ceguera en México

Overview

Posterior sub-tenon's injection of bevacizumab decreased diffuse diabetic macular edema

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Diffuse Diabetic Macular Edema

Interventions

bevacizumab (Sub-tenon´s injection)DRUG

a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)

Eligibility

Sex: ALLMin age: 25 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients with diffuse diabetic macular edema non-proliferative diabetic retinopathy Maculat thickness ≥250 μ BCVA ≥ 20/400 Without any treatment

Locations (1)

Asociación para Evitar la Ceguera en Mexico

Mexico City, Mexico City, Mexico

Outcomes

Primary Outcomes

macular volume

Time frame: baseline, 3,6 and 12 weeks

Secondary Outcomes

macular thickness

Time frame: baseline,3,6 and 12 weeks

best corrected visual acuity

Time frame: baseline, 3,6 and 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.